Spruce Biosciences Touts MPS IIIB Data, Targets Q4 BLA Submission at Oppenheimer Conference

Executives from Spruce Biosciences (NASDAQ:SPRB) outlined regulatory plans, clinical data highlights, and commercial considerations for the company’s lead program in Sanfilippo syndrome type B (MPS ...
Yahoo Finance

Spruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

Biologics License Application (BLA) Submission to U.S. FDA for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Anticipated in 1H 2026 Spruce to Host Conference Call Today at 8:30 a.m. ET "This ...
FierceBiotech

Spruce halves head count, narrowing focus to get ex-BioMarin drug to FDA

Spruce Biosciences has swept away 55% of its employees. The biotech took the action days after inking a deal for a former BioMarin rare disease candidate that it plans to file for a speedy approval ...
Hoodline

Water Main Break Brings Spruce Street To A Standstill By Penn Hospital

Spruce Street turned into a no-go zone outside the University of Pennsylvania medical complex last night, after a water main break shut down the stretch between 34th and 38th streets and choked off ...